, Pourquoi le cancer porte-t-il ce nom-là ?
, Institut National de Recherche et du Cancer, 2014.
, Fondation ARC pour la recherche sur le cancer. Le cancer en chiffres
,
610 000 personnes sont décédées en France en 2018, dont la moitié dans le département où elles sont nées -Insee Focus n°163 ,
, Fédération de l'Hospitalisation Privée : Médecine, Chirurgie, Obstétrique. Les principales causes de mortalité en France [Internet]. fhpmco.fr, 2019.
,
Approche et méthodologie générale pour l'estimation des cancers attribuables au mode de vie et à l'environnement en France métropolitaine en, Bull Épidémiologique Hebd. 26 juin, issue.21, pp.432-474, 2015. ,
, Les cancers en France en 2018 -L'essentiel des faits et chiffres (édition, 2019.
, Institut National du Cancer. Données globales d'épidémiologie des cancers
Le cancer en chiffres -Les taux de guérison [Internet]. arcagy.org, 2019. ,
Nombre et fractions de cancers attribuables au mode de vie et à l'environnement en France métropolitaine en 2015 : résultats principaux, Bull Épidémiologique Hebd. 26 juin, issue.21, pp.442-450, 2018. ,
, Fondation ARC pour la recherche sur le cancer. Les facteurs de risque et la prévention [Internet]. fondation-arc.org
, Fondation ARC pour la recherche sur le cancer. Les ondes électromagnétiques [Internet]. fondation-arc.org, 2019.
Presses universitaires de France, Le cancer. 5 e éd, pp.76-94, 2003. ,
, Fondation pour la Recherche Médicale. Cancers : du dépistage au diagnostic, au plus tôt ! [Internet]. frm.org
, Fondation contre le Cancer. Les examens [Internet]. cancer.be
,
, Cancer : les traitements et les soins de support, Fondation ARC pour la recherche sur le cancer
Aging, cancer, and cancer vaccines, Immun Ageing. 17 avr, vol.9, issue.4, 2012. ,
Pourquoi Roche s'est intéressé au système immunitaire pour lutter contre le cancer | Roche, 2017. ,
Réponse immunitaire anti-tumorale. Cours d'immunologie de L3 Pharmacie, 2014. ,
Oncology Meets Immunology: The Cancer-Immunity Cycle, Immunity. 25 juill, vol.39, issue.1, pp.1-10, 2013. ,
Qu'est-ce que le cycle de l'immunité anti-tumorale ? | Roche, 2018. ,
,
Cancer despite immunosurveillance: immunoselection and immunosubversion, Nat Rev Immunol. oct, vol.6, issue.10, pp.715-742, 2006. ,
Immunothérapie -Principes généraux ,
, Cellule cancéreuse et tissu cancéreux [Internet]. campus.cerimes.fr, Collège Français des Pathologistes (CoPath), 2011.
Rôle de CTLA-4 dans la cosignalisation négative du système immunitaire. médecine/sciences. 1 er, vol.27, pp.842-851, 2011. ,
The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer. 22 avr, vol.12, issue.4, pp.252-64, 2012. ,
Influence de PD-1 sur la synapse immunologique -Une facette de la régulation immunitaire ? médecine/sciences. 1 er déc, vol.29, pp.1080-1082, 2013. ,
Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies, Drug Discov Today. sept, vol.20, issue.9, pp.1127-1161, 2015. ,
Le cancer féminin du poumon en hausse en France [Internet]. sante.lefigaro.fr, 2018. ,
,
, Le cancer du poumon -Les cancers les plus fréquents [Internet]. e-cancer.fr, 2019.
, Cancer du poumon : points-clés [Internet]. e-cancer.fr, 2018.
, Référentiel « Carcinomes neuroendocrines bronchiques à grandes cellules
,
Epidémiologie des tumeurs de la vessie ,
, Types of Bladder Cancer: Common, Rare and More, Internet]. cancercenter.com, 2018.
L'essentiel sur le cancer du rein ,
,
Carcinome à cellules rénales ,
, Édition professionnelle du Manuel MSD, 2019.
,
, Fondation ARC pour la recherche sur le cancer. Cancers du rein : les traitements [Internet]. fondation-arc.org, 2018.
Recommandations françaises du Comité de Cancérologie de l, AFU -Actualisation, vol.28, issue.12, pp.3-31, 2018. ,
Les cancers de la tête et du cou ,
Carcinome épidermoïde et cancer de la tête et du cou ,
,
, Le lymphome hodgkinien : points clés [Internet]. e-cancer.fr
Les différents types de lymphomes de Hodgkin, Internet]. arcagy.org, 2018. ,
,
The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases, Am J Med Sci. mai, vol.105, issue.5, pp.487-511, 1893. ,
Intravenous Infusion of Bone Marrow in Patients Receiving Radiation and Chemotherapy, N Engl J Med. 12 sept, vol.257, issue.11, pp.487-511, 1957. ,
Haematopoietic Chimera in Man After Allogenic (Homologous) Bone-marrow Transplantation, Br Med J. 28 déc, vol.2, issue.5373, pp.1633-1638, 1963. ,
immunothérapie des cancers : véritable révolution thérapeutique. Laennec, Tome, vol.31, issue.2020, pp.20-34 ,
, Fondation ARC pour la recherche sur le cancer. Immunothérapie : les différentes stratégies
, Immunothérapie : mode d'action, 2017.
, , 2020.
, Prix Nobel de médecine 2018 : l'immunothérapie récompensée, 2018.
Le Nobel de médecine 2018 récompense l'immunothérapie contre le cancer ,
, , 2018.
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057), J Clin Oncol. 10 déc, vol.35, issue.35, pp.3924-3957, 2017. ,
Carboplatin and pemetrexed with or without pembrolizumab for advanced, nonsquamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study, Lancet Oncol, vol.17, issue.11, pp.1497-508, 2016. ,
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet, vol.389, pp.255-65, 2017. ,
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial, Lancet Oncol. 1 er juill, vol.17, issue.7, pp.956-65, 2016. ,
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.373, pp.1803-1816, 2015. ,
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. The Lancet, vol.389, pp.67-76, 2017. ,
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma, N Engl J Med. 22 janv, vol.372, issue.4, pp.311-320, 2015. ,
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, N Engl J Med, vol.377, issue.14, pp.1345-56, 2017. ,
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). The Lancet, vol.390, pp.1853-62, 2017. ,
Les limites des inhibiteurs de points de contrôle immunitaire et la gestion de leur toxicité. médecine/sciences. 1 er déc, vol.35, pp.949-56, 2019. ,
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial, Lancet Oncol. 1 er nov, vol.19, issue.11, pp.1480-92, 2018. ,
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer, N Engl J Med. 6 déc, vol.379, issue.23, pp.2220-2229, 2018. ,
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer, Mol Ther Oncolytics. 19 mars, vol.13, pp.1-6, 2019. ,
, Agence européenne des médicaments. YERVOY (Résumé des caractéristiques du produit, p.2020
, Agence européenne des médicaments. OPDIVO (Résumé des caractéristiques du produit, p.2020
, Agence européenne des médicaments. KEYTRUDA (Résumé des caractéristiques du produit, p.2020
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers, Clin Lung Cancer. 1 er mars, vol.19, issue.2, pp.120-129, 2018. ,
, Agence européenne des médicaments. LIBTAYO (Résumé des caractéristiques du produit, p.2020
, Agence européenne des médicaments, TECENTRIQ, vol.840
, Agence européenne des médicaments. TECENTRIQ 1200 mg, p.2020
, Agence européenne des médicaments. IMFINZI (Résumé des caractéristiques du produit, p.2020
Cancer bronchique non à petites cellules -Référentiels inter-régionaux en oncologie thoracique ,
, Agence européenne des médicaments. BAVENCIO (Résumé des caractéristiques du produit, p.2020
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group, J Immunother Cancer, vol.5, issue.1, p.95, 2017. ,
Challenges faced when identifying patients for combination immunotherapy, Future Oncol. 1 er août, vol.13, issue.18, pp.1607-1625, 2017. ,
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma, Oncotarget. 28 févr, vol.6, issue.6, pp.3479-92, 2015. ,
Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting, Eur J Cancer, vol.121, pp.192-201, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02465794
iRECIST pour (pas seulement) les nuls, J Imag Diagn Interv, vol.2, issue.2, pp.83-90, 2019. ,
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol. mars, vol.18, issue.3, pp.143-52, 2017. ,
New response evaluation criteria in solid tumours: revised RECIST guideline ,
, Eur J Cancer Oxf Engl, vol.45, issue.2, pp.228-275, 1990.
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials, J Clin Oncol Off J Am Soc Clin Oncol. 1 er déc, vol.35, issue.34, pp.3807-3821, 2017. ,
Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study, J Dermatol. févr, vol.44, issue.2, pp.117-139, 2017. ,
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes, Clin Cancer Res Off J Am Assoc Cancer Res. 15 févr, vol.22, issue.4, pp.886-94, 2016. ,
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression, JAMA Dermatol, vol.151, issue.11, pp.1206-1218, 2015. ,
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer, JAMA Oncol. mars, vol.4, issue.3, 2018. ,
Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK, Ann Oncol. 1 er sept, vol.28, p.469, 2017. ,
, Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand, vol.1
, Blockade in Patients With Non-Small-Cell Lung Cancer, J Clin Oncol. 1 er oct, vol.36, issue.28, 2018.
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications, J Clin Oncol. 1 er août, vol.37, issue.22, pp.1927-1961, 2019. ,
Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab, J Thorac Oncol. 1 er nov, vol.13, issue.11, pp.1771-1776, 2018. ,
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors, ESMO Open. 27 févr, vol.4, issue.1, 2019. ,
Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review, Crit Rev Oncol Hematol. 1 er déc, vol.120, pp.86-92, 2017. ,
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science. 5 janv, vol.359, issue.6371, pp.97-103, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02629159
Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario, Crit Rev Oncol Hematol, vol.142, pp.26-34, 2019. ,
Effets secondaires des IPP au long cours ,
Effects of antibiotics and proton pump inhibitors in NSCLC patients treated with atezolizumab and docetaxel: Pooled analysis of the OAK and POPLAR trials, Ann Oncol. 1 er déc, vol.29, p.17, 2018. ,
Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer, Lung Cancer. 1 er avr, vol.130, pp.10-17, 2019. ,
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer, Ann Oncol. 1 er juin, vol.29, issue.6, pp.1437-1481, 2018. ,
Use of broadspectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors, OncoImmunology, vol.7, issue.2, 2018. ,
Antibiotic Use and PD-1 Inhibitors: Shorter Survival in Lung Cancer, Especially When Given Intravenously. Type of Infection Also Matters, J Thorac Oncol. 1 er oct, vol.13, issue.10, p.389, 2018. ,
Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances, Front Microbiol. 12 janv, vol.6, 2016. ,
Antibiotic treatment prior to immune checkpoint inhibitor therapy as a tumor-agnostic predictive correlate of response in routine clinical practice, J Clin Oncol. 10 mars, vol.37, pp.147-147, 2019. ,
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study, Immunotherapy, vol.10, issue.14, pp.1229-1268, 2018. ,
Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events, J Immunother Cancer. 1 er déc, vol.6, issue.1, p.40, 2018. ,
, NPG Neurol -Psychiatr -Gériatrie. août, vol.12, issue.70, pp.171-81, 2012.
The Effect of Age on Thymic Function. Front Immunol, vol.4, 2013. ,
Immunosenescence and cancer, J Geriatr Oncol. 1 er juin, vol.1, issue.1, pp.20-26, 2010. ,
Immune checkpoint inhibitors and elderly people: A review, Eur J Cancer. 1 er sept, vol.82, pp.155-66, 2017. ,
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis, J Immunother Cancer. 1 er déc, vol.6, issue.1, p.26, 2018. ,
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations, Clin Cancer Res Off J Am Assoc Cancer Res. 1 er nov, vol.24, issue.21, pp.5347-56, 2018. ,
Anti-PD1 antibodies in patients aged ? 75 years with metastatic melanoma: A retrospective multicentre study, J Geriatr Oncol. avr, vol.11, issue.3, pp.515-537, 2020. ,
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade, N Engl J Med. 11 janv, vol.378, issue.2, pp.158-68, 2018. ,
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination, Nat Rev Clin Oncol. 4 août, vol.13, issue.8, pp.473-86, 2016. ,
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy, J Clin Oncol. 10 juin, vol.36, issue.17, pp.1714-68, 2018. ,
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol, vol.29, issue.4, pp.264-270, 2018. ,
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance, Nat Rev Clin Oncol. sept, vol.16, issue.9, pp.563-80, 2019. ,
Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0 [Internet, 2017. ,
Ipilimumab versus placebo after radiotherapy in patients with metastatic castrationresistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, Lancet Oncol. juin, vol.15, issue.7, pp.700-712, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02168065
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, N Engl J Med, vol.363, issue.8, pp.711-734, 2010. ,
Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer, N Engl J Med. 28 juin, vol.366, issue.26, pp.2443-54, 2012. ,
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Ann Oncol. 1 er avr, vol.27, issue.4, pp.559-74, 2016. ,
Toxicités dermatologiques des inhibiteurs de checkpoint immunologiques, Ann Dermatol Vénéréologie. mai, vol.145, issue.5, pp.313-343, 2018. ,
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies, Ann Oncol, vol.28, issue.11, pp.2860-2865, 2017. ,
, Toxicité gastro intestinale des immunothérapies du cancer. POST'U, 2018.
Thyroid disorders induced by checkpoint inhibitors, Rev Endocr Metab Disord. 21 sept, vol.19, issue.4, pp.325-358, 2018. ,
Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis, Eur J Endocrinol. 1 er sept, vol.181, issue.3, pp.211-220, 2019. ,
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management, Cancer Treat Rev. 1 er juill, vol.58, pp.70-76, 2017. ,
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy, J Clin Oncol. 1 er mars, vol.35, issue.7, pp.709-726, 2017. ,
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors, J Hepatol. 1 er juin, vol.68, issue.6, pp.1181-90, 2018. ,
Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis, Pancreatology. juin, vol.19, issue.4, pp.587-94, 2019. ,
Toxicité rénale des immunothérapies : résultats préliminaires de l'étude ImmuNoTox, Néphrologie Thérapeutique. sept, vol.14, issue.5, p.248, 2018. ,
Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report, BMC Nephrol. 27 févr, vol.19, issue.1, p.48, 2018. ,
Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020. Kidney360, vol.27, pp.130-170 ,
Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database, J Neurooncol, vol.145, issue.1, pp.1-9, 2019. ,
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. The Lancet, vol.10, p.933, 2018. ,
Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue, Curr Med Chem, vol.31, issue.11, pp.1327-1366, 2018. ,
Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153, PLOS ONE. 22 avr, vol.10, issue.4, p.124059, 2015. ,
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study, Lancet Haematol. 1 er janv, vol.6, issue.1, pp.48-57, 2019. ,
, Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1
, Anticancer Immunotherapy, Am J Ophthalmol. 1 er juin, vol.202, pp.109-126, 2019.
Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer, Arthritis Rheumatol, vol.69, issue.4, pp.687-99, 2017. ,
Ann Marie Kumfer sur Twitter ,
, , 2020.
,
Cancer immunotherapy in patients with preexisting autoimmune disorders, Semin Immunopathol. 1 er avr, vol.39, issue.3, pp.333-340, 2017. ,
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. Arthritis Rheumatol, vol.71, pp.2100-2111, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02267195
Aspects immunologiques et cliniques des transplantations d'organes. Cours d'immunologie de L3 Pharmacie, 2014. ,
PDL1 Is Required for Peripheral Transplantation Tolerance and Protection from Chronic Allograft Rejection, J Immunol Baltim Md, vol.179, issue.8, pp.5204-5214, 1950. ,
Tumor Regression and Allograft Rejection after Administration of Anti-PD-1, N Engl J Med. 3 mars, vol.374, issue.9, pp.896-904, 2016. ,
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature, J Immunother Cancer. 1 er déc, vol.7, issue.1, p.106, 2019. ,
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events, J Natl Compr Canc Netw. 1 er juin, vol.17, issue.6, pp.712-732, 2019. ,
Systematic review: colitis associated with anti-CTLA-4 therapy, Aliment Pharmacol Ther, vol.42, issue.4, pp.406-423, 2015. ,
Managing Immune Checkpoint-Blocking Antibody Side Effects, Am Soc Clin Oncol Educ Book. 1 er mai, issue.35, pp.76-83, 2015. ,
, , vol.1, 2019.
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis, Nat Med, vol.24, issue.12, pp.1804-1812, 2018. ,
Guide pour les patients ESMO : Les effets secondaires liés à l'immunothérapie, 2017. ,
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis, Cancer Immunol Immunother. juin, vol.66, issue.5, pp.581-92, 2017. ,
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade, J Oncol Pharm Pract. avr, 2019. ,
, Site internet de la FITC -Éducation thérapeutique
,
, Consensus et recommandations de la SFE -Effets secondaires endocriniens des nouvelles thérapies anti-cancéreuses, 2018.
,
Les infections sur cathéters : diagnostic et prise en charge, 2019. ,
,
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors), Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 1 er juin, vol.24, issue.2, pp.95-107, 2018. ,
Initiative des High 5s -Medication Reconciliation. Rapport d'expérimentation sur la mise en oeuvre de la conciliation des traitements médicamenteux par neuf établissements de santé français ,
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials, Ther Adv Med Oncol, vol.16, issue.2020 ,
05 Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%, J Thorac Oncol. 1 er oct, vol.13, issue.10, pp.367-375, 2018. ,
Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders, Front Med, vol.7, issue.2020 ,
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers, Br J Cancer. 26 sept, vol.117, issue.7, pp.913-933, 2017. ,
Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?, J Immunother Cancer. 28 mars, vol.7, issue.1, p.85, 2019. ,
Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors, Oncotarget. 14 déc, vol.8, issue.69, pp.114268-80, 2017. ,
Immune-related adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer. 1 er févr, vol.54, pp.139-187, 2016. ,
Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution, Anticancer Res. 1 er févr, vol.39, issue.2, pp.781-90, 2019. ,